Verona Pharma plc financial data

Symbol
VRNA
Location
London, United Kingdom
Fiscal year end
31 December
Latest financial report
10-Q - Q2 2025 - 06 Aug 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1047% % -33%
Quick Ratio 15% %
Debt-to-equity 133% % 187%
Return On Equity -39% % 30%
Return On Assets -17% % 56%
Operating Margin -25% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 681,056,022 shares 5%
Common Stock, Shares, Outstanding 687,930,486 shares 6.1%
Entity Public Float $1,100,000,000 USD -27%
Common Stock, Value, Issued $45,021,000 USD 5.3%
Weighted Average Number of Shares Outstanding, Basic 685,155,000 shares 5.7%
Weighted Average Number of Shares Outstanding, Diluted 727,223,000 shares 12%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $221,673,000 USD
Research and Development Expense $12,950,000 USD -33%
General and Administrative Expense $221,520,000 USD 127%
Operating Income (Loss) $56,018,000 USD 57%
Nonoperating Income (Expense) $16,926,000 USD -331%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $72,944,000 USD 41%
Income Tax Expense (Benefit) $8,243,000 USD 369%
Net Income (Loss) Attributable to Parent $81,187,000 USD 35%
Earnings Per Share, Basic 0 USD/shares 40%
Earnings Per Share, Diluted 0 USD/shares 40%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $438,016,000 USD 8.3%
Accounts Receivable, after Allowance for Credit Loss, Current $82,858,000 USD
Inventory, Net $8,612,000 USD
Other Assets, Current $3,872,000 USD 50%
Assets, Current $548,851,000 USD 32%
Property, Plant and Equipment, Net $991,000 USD 2152%
Operating Lease, Right-of-Use Asset $1,574,000 USD -30%
Goodwill $545,000 USD 0%
Assets $572,871,000 USD 32%
Accounts Payable, Current $3,434,000 USD -17%
Employee-related Liabilities, Current $7,929,000 USD 100%
Accrued Liabilities, Current $43,328,000 USD 121%
Contract with Customer, Liability, Current $0 USD
Liabilities, Current $51,238,000 USD 6%
Contract with Customer, Liability, Noncurrent $105,420,000 USD
Operating Lease, Liability, Noncurrent $926,000 USD -37%
Liabilities $294,598,000 USD 11%
Accumulated Other Comprehensive Income (Loss), Net of Tax $4,601,000 USD 0%
Retained Earnings (Accumulated Deficit) $567,101,000 USD -17%
Stockholders' Equity Attributable to Parent $278,273,000 USD 65%
Liabilities and Equity $572,871,000 USD 32%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $11,561,000 USD 15%
Net Cash Provided by (Used in) Financing Activities $13,457,000 USD
Net Cash Provided by (Used in) Investing Activities $535,000 USD -3244%
Common Stock, Shares, Issued 703,189,462 shares 5.3%
Common Stock, Par or Stated Value Per Share 0.05 GBP/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,658,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $438,016,000 USD 8.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities $10,151,000 USD 988%
Deferred Tax Assets, Valuation Allowance $98,522,000 USD 77%
Deferred Tax Assets, Gross $180,729,000 USD 65%
Operating Lease, Liability $2,361,000 USD -20%
Payments to Acquire Property, Plant, and Equipment $535,000 USD 3244%
Lessee, Operating Lease, Liability, to be Paid $2,736,000 USD -24%
Operating Lease, Liability, Current $1,014,000 USD -1.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two $841,000 USD -0.12%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,113,000 USD -5.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $375,000 USD -41%
Lessee, Operating Lease, Liability, to be Paid, Year Three $782,000 USD -0.76%
Deferred Tax Assets, Operating Loss Carryforwards $65,265,000 USD 21%
Additional Paid in Capital $805,918,000 USD 31%
Depreciation, Depletion and Amortization $295,000 USD 12%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $93,683,000 USD 218%
Interest Expense $13,848,000 USD 732%